We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Research Reports for Facebook, DuPont, Gilead & Others
Read MoreHide Full Article
Thursday, July 28, 2016
Today's Research Daily write-up features reports on 16 stocks, including DuPont (DD - Free Report) , Facebook and Gilead (GILD - Free Report) . These 16 research reports have been hand-picked from the more than 80 reports issued by our analyst team today.
Facebook’s blowout quarterly numbers should help sustain the stock's positive momentum in the coming days. This report reconfirmed the company's status as a technology powerhouse with an enviable future earnings potential. The analyst likes the company’s huge user and advertiser base, higher engagement levels along with monetization opportunities presented by the Instagram, Oculus, Messenger and WhatsApp properties. (You can read the full research report on FB here.)
Buy-rated DuPont shares have outperformed the broader market lately, with the stock up more than 8% in the last four weeks. The chemical and life-sciences giant, which remains in the midst of a transformational match-up with Dow Chemicals, came out strong Q2 results and guided higher. The analyst likes the company’s new product launches and productivity actions. The planned mega-merger with Dow is also expected to create significant synergies. DuPont's committment to shareholder returns through dividends and buybacks remains another major positive. (You can read the full research report on DD here.)
Gilead remains in a tough spot, with investors increasingly becoming doubtful about its near-term growth outlook following competitive challenges to its hepatitis C franchise and limited oncology success. No doubt the stock is down almost 20% year to date. These questions notwithstanding, the analyst likes the drugmaker’s strong HIV and HCV portfolio and pipeline products that will help diversify its business beyond antivirals into other therapeutic areas. (You can read the full research report on GILD here.)
Other noteworthy reports we are featuring today include Goldman Sachs (GS - Free Report) , Analog Devices (ADI - Free Report) and Macy’s (M - Free Report) .
You can find all of today's stock research reports here.
Sheraz Mian
Director of Research
Note: Sheraz Mian regularly provides earnings analysis on Zacks.com and appears frequently in the print and electronic media. His weekly earnings related articles includeEarnings TrendsandEarnings Preview. He also provides weekly commentary to Zacks Premium subscribers and manages the Zacks Focus List and Top 10 portfolios.
If you want an email notification each time Sheraz publishes a new article, pleaseclick here.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Research Reports for Facebook, DuPont, Gilead & Others
Thursday, July 28, 2016
Today's Research Daily write-up features reports on 16 stocks, including DuPont (DD - Free Report) , Facebook and Gilead (GILD - Free Report) . These 16 research reports have been hand-picked from the more than 80 reports issued by our analyst team today.
Facebook’s blowout quarterly numbers should help sustain the stock's positive momentum in the coming days. This report reconfirmed the company's status as a technology powerhouse with an enviable future earnings potential. The analyst likes the company’s huge user and advertiser base, higher engagement levels along with monetization opportunities presented by the Instagram, Oculus, Messenger and WhatsApp properties. (You can read the full research report on FB here.)
Buy-rated DuPont shares have outperformed the broader market lately, with the stock up more than 8% in the last four weeks. The chemical and life-sciences giant, which remains in the midst of a transformational match-up with Dow Chemicals, came out strong Q2 results and guided higher. The analyst likes the company’s new product launches and productivity actions. The planned mega-merger with Dow is also expected to create significant synergies. DuPont's committment to shareholder returns through dividends and buybacks remains another major positive. (You can read the full research report on DD here.)
Gilead remains in a tough spot, with investors increasingly becoming doubtful about its near-term growth outlook following competitive challenges to its hepatitis C franchise and limited oncology success. No doubt the stock is down almost 20% year to date. These questions notwithstanding, the analyst likes the drugmaker’s strong HIV and HCV portfolio and pipeline products that will help diversify its business beyond antivirals into other therapeutic areas. (You can read the full research report on GILD here.)
Other noteworthy reports we are featuring today include Goldman Sachs (GS - Free Report) , Analog Devices (ADI - Free Report) and Macy’s (M - Free Report) .
You can find all of today's stock research reports here.
Sheraz Mian
Director of Research
Note: Sheraz Mian regularly provides earnings analysis on Zacks.com and appears frequently in the print and electronic media. His weekly earnings related articles include Earnings Trends and Earnings Preview. He also provides weekly commentary to Zacks Premium subscribers and manages the Zacks Focus List and Top 10 portfolios.
If you want an email notification each time Sheraz publishes a new article, please click here.